Revenue Milestones: Social media commentary highlighted Eli Lilly's revenue run-rate surpassing many established firms including IBM and American Express. Observers drew attention to the firm's market capitalization trajectory and sustained earnings power. These points framed ongoing investor focus on its core pharmaceutical operations.
AI Ventures: Discussions centered on the company's allocation of capital toward AI-driven drug discovery and dedicated data infrastructure. Participants noted partnerships and internal platforms aimed at accelerating innovation. Such developments were presented as broadening the scope of growth opportunities.
Strategic Moves: Chatter included potential acquisitions in emerging treatment categories such as psychedelics for mental health. Users referenced competitive dynamics in weight-loss and related therapies. The prevailing tone remained forward-looking amid these developments.
Note: This discussion summary was generated from an AI condensation of post data.
Eli Lilly and Company Insider Trading Activity
Eli Lilly and Company insiders have traded $LLY stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $LLY stock by insiders over the last 6 months:
- ILYA YUFFA (EVP&Pres, LLY USA&Global Capab) sold 2,500 shares for an estimated $2,876,925
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Eli Lilly and Company Revenue
Eli Lilly and Company had revenues of $19.8B in Q1 2026. This is an increase of 55.55% from the same period in the prior year.
You can track LLY financials on Quiver Quantitative's LLY stock page.
You can access data on LLY stock through the Quiver Quantitative API.
Eli Lilly and Company Congressional Stock Trading
Members of Congress have traded $LLY stock 11 times in the past 6 months. Of those trades, 5 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $LLY stock by members of Congress over the last 6 months:
- REPRESENTATIVE DAN NEWHOUSE sold up to $15,000 on 07/10.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 2 purchases worth up to $115,000 on 06/10, 04/14 and 1 sale worth up to $15,000 on 03/13.
- REPRESENTATIVE LIZZIE FLETCHER sold up to $15,000 on 04/08.
- REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 2 purchases worth up to $30,000 on 04/02 and 0 sales.
- SENATOR ALAN ARMSTRONG sold up to $15,000 on 03/27.
- REPRESENTATIVE DAVID TAYLOR has traded it 2 times. They made 1 purchase worth up to $15,000 on 02/26 and 1 sale worth up to $15,000 on 02/09.
- SENATOR ANGUS S. KING JR. sold up to $15,000 on 02/13.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Eli Lilly and Company Hedge Fund Activity
We have seen 2,169 institutional investors add shares of Eli Lilly and Company stock to their portfolio, and 1,653 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- J. STERN & CO. LLP removed 4,042,726 shares (-99.9%) from their portfolio in Q1 2026, for an estimated $3,692,666,355
- CAPITAL INTERNATIONAL INVESTORS removed 3,752,688 shares (-38.0%) from their portfolio in Q1 2026, for an estimated $3,427,742,746
- STATE FARM MUTUAL AUTOMOBILE INSURANCE CO removed 1,721,029 shares (-13.8%) from their portfolio in Q1 2026, for an estimated $1,572,005,098
- LILLY ENDOWMENT INC removed 1,520,000 shares (-1.7%) from their portfolio in Q2 2026, for an estimated $1,823,133,600
- FIFTH THIRD BANCORP added 1,497,423 shares (+321.3%) to their portfolio in Q1 2026, for an estimated $1,367,761,142
- DIAMANT ASSET MANAGEMENT, INC. added 1,069,720 shares (+119923.8%) to their portfolio in Q1 2026, for an estimated $977,092,945
- ASSENAGON ASSET MANAGEMENT S.A. removed 1,049,209 shares (-67.7%) from their portfolio in Q2 2026, for an estimated $1,258,452,750
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Eli Lilly and Company Price Targets
Multiple analysts have issued price targets for $LLY recently. We have seen 14 analysts offer price targets for $LLY in the last 6 months, with a median target of $1336.0.
Here are some recent targets:
- Trung Huynh from RBC Capital set a target price of $1500.0 on 07/08/2026
- Robyn Karnauskas from Truist Securities set a target price of $1370.0 on 07/08/2026
- Terence Flynn from Morgan Stanley set a target price of $1347.0 on 07/08/2026
- Chris Schott from JP Morgan set a target price of $1400.0 on 07/07/2026
- Carter Gould from Cantor Fitzgerald set a target price of $1350.0 on 07/06/2026
- David Risinger from Leerink Partners set a target price of $1232.0 on 06/25/2026
- Akash Tewari from Jefferies set a target price of $1350.0 on 06/09/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
